Rhythm Biosciences Ltd. ( (AU:RHY) ) has provided an announcement.
Rhythm Biosciences Ltd has successfully maintained its ISO 13485:2016 certification for the seventh consecutive year, with an extended scope that now includes hardware development as part of its ColoSTAT® system. This certification supports the company’s market entry strategy by enhancing regulatory approvals and market confidence, reinforcing its operational credibility, and validating its robust quality systems. The certification is crucial for the international launch of ColoSTAT® and the company’s ability to supply high-quality raw materials for in-house IVD applications.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing simple and affordable blood tests for early cancer detection. The company aims to improve patient outcomes by detecting cancers at the earliest possible stage, thereby reducing the global cancer burden and saving lives. Founded in 2017 and headquartered in Melbourne, Australia, Rhythm collaborates with global partners to commercialize and distribute its diagnostic solutions.
YTD Price Performance: -10.34%
Average Trading Volume: 308,230
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$22.61M
Find detailed analytics on RHY stock on TipRanks’ Stock Analysis page.